Managing Directors Vincent Mekles and Joe Shepley outline key steps organizations should take to proactively address the new Rule including how to assess employee and vendor risk and build defensible compliance controls.
In the second article of a four-part series, the Insurance sector within the Financial Services Industry Group explores how reinsurance sidecars are delivering historic returns.
For decades, the United States has shouldered a disproportionate share of global pharmaceutical costs, accounting for 70% of global biopharma profits and over 80% of new drug launches. While this has helped drive significant medical innovation and supported the majority of global drug launches, it has also resulted in higher out-of-pocket costs for American patients.